AI didn’t change the fundamentals of B2B targeting. It changed who can actually execute at scale — and how fast.
Account-based marketing has been talked about in life sciences for years. The concept is simple: instead of casting a wide net and hoping something sticks, you define a precise target, build a verified list, and reach out with something relevant to that specific person at that specific company.
In theory, everyone agrees this is the right approach for niche B2B — especially in pharma services, biotech tools, and contract research, where your total addressable market might be 300 companies in Europe and your buyer is a very specific person with a very specific job. In practice, most companies are doing broadcast marketing with a spreadsheet bolted on the side and calling it ABM.
What’s changed in the last 18 months isn’t the strategy. It’s the execution layer. And if you’re not aware of what’s now possible — and accessible without an enterprise budget — you’re working with tools from a different era.
Start with the ICP
Before any tool, before any database, before the first search query — you need a clear ideal customer profile. This sounds obvious. It isn’t, based on how most life sciences companies actually approach this.
An ICP is not “pharma companies in Germany.” It’s something like: early-stage biotech companies with small molecule pipelines that are entering or approaching preclinical development, operating in Western Europe, without in-house analytical capabilities. Two sentences. Completely different targeting exercise.
When you’re working with a highly specialized service provider — a niche CRO, a contract lab, an analytical services company — the target universe is genuinely small. That’s the whole point of ABM: it makes sense precisely because the market is this concentrated. And when the market is this small, precision isn’t optional. It’s the entire game.
The ICP should be specific enough to produce a disqualification list, not just a target list. If you can’t explain clearly why a company doesn’t belong, your criteria aren’t tight enough yet.
Disqualifiers matter just as much as qualifiers. Depending on the service, that might mean filtering out biologics-only pipelines, companies with established in-house infrastructure, CROs that are actually competitors, or companies at a stage where all vendor decisions are already locked. Getting this wrong costs time and credibility in outreach. A cold call to a company that has no reason to ever use your service is worse than no call at all.
The data problem in life sciences — and why it’s actually solvable now
Life sciences target lists have a specific problem: the right sources are technical and scattered, and the wrong sources are everywhere. LinkedIn alone is not a sourcing strategy. Neither is buying a generic “pharma contacts DACH” list from a data vendor and assuming it maps to your actual ICP.
Good sources exist — they’re just not obvious if you haven’t done this kind of work before. Clinical trial registries, industry association directories, university spin-off portfolios, national biotech association sites, investor portfolio lists — these are underused precisely because they require real research to interpret. Cross-referencing a company’s pipeline against their public communications to check therapy area, development stage, and outsourcing posture: that used to take hours per company.
That’s the part AI has transformed. Not the sourcing logic — you still need to know where to look and what you’re looking for. But the research layer sitting on top: screening dozens of companies for fit against specific criteria, verifying whether a startup is still active, checking whether a CRO actually offers a given service — this batch qualification work that previously required a full-time analyst for weeks can now be structured and executed dramatically faster. We’re talking a 4–6x reduction in time for this layer, at comparable or better accuracy, when the workflow is set up correctly.
The sourcing logic still requires expertise. The execution layer — batch research, qualification, enrichment — is where AI changes the math entirely.
The 2026 stack — what’s actually worth using
There’s no shortage of tools claiming to solve prospecting. Most are either expensive enterprise platforms with limited European data, or enrichment tools that return low-confidence results for smaller companies that don’t have significant web presence. Here’s what actually works for life sciences ABM at this level:
- Specialized registries
Clinical trial databases, association directories, regulatory filings — the most underused prospecting sources in European life sciences. Tells you who’s doing what, at what stage.
- AI research layer
For batch qualification: screening companies against ICP criteria at scale, verifying web presence, checking service scope. Not a replacement for judgment — an accelerator for the research work.
- Clay & co.
Enrichment and waterfall logic. Feed it a verified company list, run sequential enrichment steps to fill contact fields — without manual lookup for each record.
- Sales Navigator
Still the most reliable source for persona identification within target companies. No shortcut here — but once your company list is clean, this layer is straightforward.
- LinkedIn automation
Connection sequencing tools like Dripify work — but use them carefully. Account restrictions are a real risk, even with campaigns paused. Volume limits exist for a reason.
- Phone outreach
For technical B2B in life sciences, phone qualification still converts. A good agency with a verified list and a proper briefing closes the loop that digital touch alone can’t.
What’s new isn’t any single one of these tools — it’s the combination, and specifically the AI research layer sitting between raw sourcing and enrichment. That middle step used to be where time disappeared. Now it’s where you build a real advantage, if you know how to structure the workflow.
The verification problem nobody talks about
AI-enriched data is faster to produce than manually researched data. It is not automatically more accurate. This is the thing that gets consistently glossed over in “AI for prospecting” content.
When building target lists for life sciences clients, every qualifying company needs its website checked — not because we don’t trust the source, but because the source is usually one or two data points, and you need the full picture to make a reliable call. Is this company still active? Does their pipeline still match the profile? Did they recently announce a partnership that changes their outsourcing needs? Did a competitor just add the exact service you’re selling?
Automated enrichment excels at structured fields: phone numbers, LinkedIn profiles, firmographic data. It is not reliable for nuanced qualification decisions in a technical niche. That human layer still needs to exist, and that’s precisely where domain expertise matters.
The goal is a verified list, not a large one. 200 qualified companies beats 2,000 unqualified ones every time — especially when your outreach channel is direct human contact.
What this means in practice
If you’re a specialized service provider in life sciences — a contract lab, an analytical CRO, a niche technology provider — and your outreach isn’t converting, the issue is usually not the message. It’s the list.
Most specialized companies are still marketing to audiences that are too broad, using lists that haven’t been properly qualified, targeting personas that haven’t been verified at the company level. The message lands on the wrong person at the wrong company and nothing happens. The conclusion becomes “ABM doesn’t work for us” or “the agency underdelivered.” Neither is usually true.
The real gap is in the research and qualification layer. And that’s exactly where the combination of domain expertise and the current AI toolset closes the gap in a way that simply wasn’t feasible at this cost level two or three years ago. A thorough, verified target list for a niche European market — multiple segments, a few hundred companies, full contact enrichment — is now a weeks-long project rather than a months-long one.
For companies that figure this out first, the advantage is real. Competitors are still buying broad lists or doing manual research at the old speed. You’re running structured AI-assisted qualification against specialized sources, enriching with Clay, and running sequences against a list you actually trust.
Working on ABM in life sciences? At Nuna Digital we work with specialized pharma, biotech and life sciences companies on market intelligence, target list development, and outreach strategy. Happy to talk through what’s realistic for your segment.
